Qingyong Li

Title: Innovations of Qingyong Li in Cancer Treatment

Introduction

Qingyong Li is a notable inventor based in Hangzhou, China. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on personalized precision medicine, aiming to improve therapeutic outcomes for patients suffering from various human diseases.

Latest Patents

Qingyong Li holds a patent for the "Matter of composition, synthesis, formulation and application of FL118 platform positions 7 and 9-derived analogues for treatment of human disease." This patent describes the chemical synthesis, matter of compositions, formulation, function, methods, and uses of FL118 platform positions 7 and/or 9-derived analogues for treating cancer or other human diseases. The compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate, or reverse cancer phenotypes. This invention aims to realize unique personalized cancer treatment through the application of a series of structurally relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways. He has 1 patent to his name.

Career Highlights

Qingyong Li is associated with Canget Biotek Pharma LLC, where he continues to advance his research in cancer therapeutics. His work is characterized by a commitment to developing innovative solutions that address the complexities of cancer treatment.

Collaborations

He collaborates with notable colleagues, including Xiang Ling and Fengzhi Li, to further enhance the impact of his research in the field of oncology.

Conclusion

Qingyong Li's innovative contributions to cancer treatment exemplify the potential of personalized medicine in improving patient outcomes. His dedication to research and development continues to pave the way for advancements in therapeutic strategies against human diseases.